United States 119th Congress Status: Passed Senate Bipartisan · 6 D · 3 R cosponsors

S 1838 — DeOndra Dixon INCLUDE Project Act of 2026

Last action — Held at the desk.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill has passed the Senate. Introduced May 21, 2025. It now moves to the second chamber.

Next likely step: consideration and a floor vote in the House.

Odds of enactment

Moderate chance

Based on the sponsor, cosponsors, and committee posture, this bill has a moderate chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 54% · moderate confidence
  • Passed Senate

    Current position in the legislative process.

  • 9 sponsors

    1 primary, 8 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (6 D · 3 R) — cross-party backing.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

The bill addresses inclusivity in educational projects related to individuals with disabilities.

This legislation promotes the participation of individuals with disabilities in educational programs. It aims to improve access and support for these individuals in various learning environments.

What this means for you
  • Families: This means families of individuals with disabilities may see improved educational resources and support.

Bill Text

What changed in the latest version

61 added · 89 removed

Plain-language change summary

The amended bill introduces a section specifically focused on Down syndrome research, establishing the "INclude Project," which will involve a program of research, training, and investigation by the Director of NIH. The project will prioritize high-risk research on trisomy 21 and promote studies throughout the lifespan of individuals with Down syndrome, including the development of new interventions and therapies. This change emphasizes the importance of understanding the co-occurring conditions associated with Down syndrome and aims to improve diagnosis and support for affected individuals.

→
Previous
Latest
1838 Introduced in Senate (IS)] <DOC> 119th CONGRESS 1st Session S.
1838 Engrossed in Senate (ES)] <DOC> 119th CONGRESS 2d Session S.
1838 To amend the Public Health Service Act to authorize the Secretary of Health and Human Services to carry out a program of research, training, and investigation related to Down syndrome, and for other purposes.
1838 _______________________________________________________________________ AN ACT To amend the Public Health Service Act to authorize the Secretary of Health and Human Services to carry out a program of research, training, and investigation related to Down syndrome, and for other purposes.
_______________________________________________________________________ IN THE SENATE OF THE UNITED STATES May 21, 2025 Mr.
Hickenlooper (for himself, Mr.
Moran, Mr.
Booker, and Mr.
Mullin) introduced the following bill;
which was read twice and referred to the Committee on Health, Education, Labor, and Pensions _______________________________________________________________________ A BILL To amend the Public Health Service Act to authorize the Secretary of Health and Human Services to carry out a program of research, training, and investigation related to Down syndrome, and for other purposes.
This Act may be cited as the ``DeOndra Dixon INCLUDE Project Act of 2025''.
This Act may be cited as the ``DeOndra Dixon INCLUDE Project Act of 2026''.
FINDINGS.
DEONDRA DIXON INCLUDE PROJECT.
Congress finds the following:
Part B of title IV of the Public Health Service Act (42 U.S.C.
(1) Down syndrome is the most common chromosomal disorder.
284 et seq.) is amended by adding at the end the following:
Each year, about 6,000 babies born in the United States have Down syndrome, affecting about 1 in every 700 babies born.
(2) Individuals with Down syndrome have a full or partial extra copy of chromosome 21 that leads to certain physical, intellectual, and developmental challenges.
(3) Life expectancy of individuals with Down syndrome in the United States has increased dramatically in recent decades.
In 1960, the average life expectancy was about 10 years.
Today, the average life expectancy of an individual with Down syndrome is nearly 60 years.
(4) Individuals with Down syndrome can attend school, work, make their own life decisions, have meaningful relationships, vote, and contribute to society.
(5) Individuals with Down syndrome are at an increased risk for certain medical conditions, such as autoimmune disorders, leukemia, congenital heart disease, sleep dysfunction, and Alzheimer's disease, but may be at a decreased risk for other conditions.
(6) Research and medical care supporting individuals with Down syndrome and their unique disease profile will improve health outcomes and may potentially lead to treatments for individuals born with or without Down syndrome who suffer from diseases associated with that unique profile.
SEC.
3.
DOWN SYNDROME RESEARCH.
Part A of title IV of the Public Health Service Act (42 U.S.C.
281 et seq.) is amended by adding at the end the following:
404P.
409K.
``(a) In General.--The Secretary, acting through the Office of the Director of NIH, and in consultation with other Federal agencies and partners, shall carry out, directly or through grants or contracts, a program of research, training, and investigation related to Down syndrome to be known as the INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE Project or the INCLUDE Project.
``(a) In General.--The Director of NIH shall carry out a program of research, training, and investigation related to Down syndrome to be known as the `INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE Project' or the `INCLUDE Project'.
``(b) Program Elements.--The program under subsection (a) shall include research, training, and investigation related to-- ``(1) high-risk, high reward basic science studies of the effects of chromosome 21 on human development and health;
``(b) Program Elements.--The program under subsection (a) shall include-- ``(1) high-risk, high-reward research on the effects of trisomy 21 on human development and health;
``(2) assembling and maintaining a large study population of individuals with Down syndrome;
``(2) promoting research for participants with Down syndrome across the lifespan, including cohort studies to facilitate improved understanding of Down syndrome and co- occurring conditions and development of new interventions;
``(3) expanding the number of clinical trials that are inclusive of, or expressly for, individuals with Down syndrome, including novel biomedical and pharmacological interventions and other therapies designed to promote or enhance activities of daily living;
``(3) expanding the number of clinical trials that are inclusive of, or expressly for, participants with Down syndrome, including novel biomedical and pharmacological interventions and other therapies designed to promote or enhance activities of daily living;
``(4) the biological mechanisms in individuals with Down syndrome responsible for structural and functional anomalies in cells, tissues, and organs, cognitive and behavioral dysfunction, and stunted growth;
``(4) research on the biological mechanisms in individuals with Down syndrome pertaining to structural, functional, and behavioral anomalies and dysfunction as well as stunted growth;
``(5) the identification of biomarkers for the detection of risk factors, diagnosis, and customized interventions and treatments for conditions co-occurring with Down syndrome;
``(5) supporting research to improve diagnosis and treatment of conditions co-occurring with Down syndrome, including the identification of biomarkers related to risk factors, diagnosis, and clinical research and therapeutics;
``(6) why several co-occurring conditions, such as Alzheimer's disease and autoimmunity, are prevalent in individuals with Down syndrome and how such conditions can be treated concurrently with Down syndrome;
``(6) research on the causes of increased prevalence, and concurrent treatment, of co-occurring conditions, such as Alzheimer's disease and related dementias and autoimmunity, in individuals with Down syndrome;
and ``(7) improving the quality of life of individuals with Down syndrome and their families.
and ``(7) research, training, and investigation on improving the quality of life of individuals with Down syndrome and their families.
Prioritizing Nonduplicative Research.--The Secretary shall ensure that-- ``(1) the programs and activities of the institutes, centers, agencies, and offices of the National Institutes of Health relating to Down syndrome and co-occurring conditions are coordinated, including through the Division of Program Coordination, Planning, and Strategic Initiatives under sections 402(b)(7) and 402A(c);
Prioritizing Nonduplicative Research.--The Director of NIH shall ensure that-- ``(1) the programs and activities of the institutes and centers of the National Institutes of Health relating to Down syndrome and co-occurring conditions are coordinated, including through the Office of the Director of NIH and priority-setting reviews conducted pursuant to section 402(b)(3);
and ``(2) such institutes, centers, agencies, and offices prioritize, as appropriate, Down syndrome research that does not duplicate existing research activities of the National Institutes of Health.
and ``(2) such institutes and centers, prioritize, as appropriate, Down syndrome research that does not duplicate existing research activities of the National Institutes of Health.
``(d) Technical Assistance.--The Secretary shall provide technical assistance to grantees and other involved entities, as appropriate, for carrying out activities pursuant to this section.
``(d) Consultation With Stakeholders.--In carrying out activities under this section, the Director of NIH shall, as appropriate and to the maximum extent feasible, consult with relevant stakeholders, including patient advocates, to ensure that such activities take into consideration the needs of individuals with Down syndrome.
``(e) Biennial Reports to Congress.-- ``(1) In general.--The Secretary shall submit, on a biennial basis, to the Committee on Energy and Commerce and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the Senate, a report that catalogs the research conducted or supported under this section.
``(e) Biennial Reports to Congress.-- ``(1) In general.--The Director of NIH shall submit, on a biennial basis, to the Committee on Energy and Commerce and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the Senate, a report that catalogs the research conducted or supported under this section.
``(2) Contents.--Each report under paragraph (1) shall include-- ``(A) identification of the institute, center, agency, office, or entity involved;
``(2) Contents.--Each report under paragraph (1) shall include-- ``(A) identification of the institute or center involved;
``(B) a statement of whether the research is or was being carried out directly by the institute, center, agency, office, or entity or by multiple institutes, centers, agencies, offices, or entities;
``(B) a statement of whether the research is or was being carried out directly by such institute or center or by multiple institutes and centers;
Show all 46 changed rows (6 more)
Previous
Latest
and ``(C) identification of any resulting real world evidence that is or may be used for clinical research and medical care for patients with Down syndrome.''.
and ``(C) identification of any resulting real-world evidence that is or may be used for clinical research and medical care for patients with Down syndrome.''.
<all>
Passed the Senate August 6, 2026.
Attest:
Secretary.
119th CONGRESS 2d Session S.
1838 _______________________________________________________________________ AN ACT To amend the Public Health Service Act to authorize the Secretary of Health and Human Services to carry out a program of research, training, and investigation related to Down syndrome, and for other purposes.
View plain text versions (2)

How this bill changes current law

1 change Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

This bill adds a new section to the Public Health Service Act to establish a program of research, training, and investigation related to Down syndrome.

  • 42 U.S.C. 284

    SEC. 409K. DOWN SYNDROME RESEARCH. (a) In General.--The Director of NIH shall carry out a program of research, training, and investigation related to Down syndrome to be known as the `INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE Project' or the `INCLUDE Project'. (b) Program Elements.--The program under subsection (a) shall include-- (1) high-risk, high-reward research on the effects of trisomy 21 on human development and health; (2) promoting research for participants with Down syndrome across the lifespan, including cohort studies to facilitate improved understanding of Down syndrome and co- occurring conditions and development of new interventions; (3) expanding the number of clinical trials that are inclusive of, or expressly for, participants with Down syndrome, including novel biomedical and pharmacological interventions and other therapies designed to promote or enhance activities of daily living; (4) research on the biological mechanisms in individuals with Down syndrome pertaining to structural, functional, and behavioral anomalies and dysfunction as well as stunted growth; (5) supporting research to improve diagnosis and treatment of conditions co-occurring with Down syndrome, including the identification of biomarkers related to risk factors, diagnosis, and clinical research and therapeutics; (6) research on the causes of increased prevalence, and concurrent treatment, of co-occurring conditions, such as Alzheimer's disease and related dementias and autoimmunity, in individuals with Down syndrome; (7) research, training, and investigation on improving the quality of life of individuals with Down syndrome and their families. (c) Coordination; Prioritizing Nonduplicative Research.--The Director of NIH shall ensure that-- (1) the programs and activities of the institutes and centers of the National Institutes of Health relating to Down syndrome and co-occurring conditions are coordinated, including through the Office of the Director of NIH and priority-setting reviews conducted pursuant to section 402(b)(3); and (2) such institutes and centers, prioritize, as appropriate, Down syndrome research that does not duplicate existing research activities of the National Institutes of Health. (d) Consultation With Stakeholders.--In carrying out activities under this section, the Director of NIH shall, as appropriate and to the maximum extent feasible, consult with relevant stakeholders, including patient advocates, to ensure that such activities take into consideration the needs of individuals with Down syndrome. (e) Biennial Reports to Congress.-- (1) In general.--The Director of NIH shall submit, on a biennial basis, to the Committee on Energy and Commerce and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the Senate, a report that catalogs the research conducted or supported under this section. (2) Contents.--Each report under paragraph (1) shall include-- (A) identification of the institute or center involved; (B) a statement of whether the research is or was being carried out directly by such institute or center or by multiple institutes and centers; and (C) identification of any resulting real-world evidence that is or may be used for clinical research and medical care for patients with Down syndrome.

    This addition establishes a comprehensive program focusing on Down syndrome research, including multiple aspects such as clinical trials, training, and biennial reporting.

Action History

  1. Introduced in Senate

  2. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  3. Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.

  4. Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.

  5. Measure laid before Senate by unanimous consent. (consideration: CR S4495-4498)

  6. Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote. (text of amendment in the nature of a substitute: CR S4495-4496)

  7. Passed Senate with an amendment by Voice Vote. (text of amendment in the nature of a substitute: CR S4495-4496)

  8. Message on Senate action sent to the House.

  9. Received in the House.

  10. Held at the desk.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 8 co-sponsors · 538 not signed on

Sponsors (1)

Co-sponsors (8)

Not signed on (538)

538 members have not signed on to this bill.

Show all 538 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors S 1838?
S 1838 is sponsored by Moran, Jerry (Republican), Booker, Cory A. (Democratic), Mullin, Markwayne (Republican), Bennet, Michael F. (Democratic), Padilla, Alex (Democratic), Capito, Shelley Moore (Republican), Coons, Christopher A. (Democratic), Van Hollen, Chris (Democratic), and Hickenlooper, John W. (Democratic).
What is the current status of S 1838?
This bill has passed the Senate. Introduced May 21, 2025. It now moves to the second chamber.
Where can I track S 1838?
Track S 1838 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 1838

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of S 1838

Last checked for changes about 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →